Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia

Parkinson’s disease (PD) is the second most common neurodegenerative disease. Pharmacotherapy with L-DOPA remains the gold-standard therapy for PD, but is often limited by the development of the common side effect of L-DOPA-induced dyskinesia (LID), which can become debilitating. The only effective...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Exp Neurol
Main Authors: Bartlett, Mitchell J., Flores, Andrew J., Ye, Tony, Smidt, Saskia I., Dollish, Hannah K., Stancati, Jennifer A., Farrell, Drew C., Parent, Kate L., Doyle, Kristian P., Besselsen, David G., Heien, Michael L., Cowen, Stephen L., Steece-Collier, Kathy, Sherman, Scott J., Falk, Torsten
Format: Artigo
Sprog:Inglês
Udgivet: 2020
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7518549/
https://ncbi.nlm.nih.gov/pubmed/32717354
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.expneurol.2020.113413
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker